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Betablockers induce cardiac chronotropic incompetence
nervous systems [9]. An increase in organ perfusion in advanced
cirrhosis can only be accomplished by a heart rate mediated
increase in cardiac output. If BB abolish the cardiac compensatory
reserve during such circulatory challenges the cirrhotic circula-
tion becomes extremely vulnerable.
We believe that the study strongly suggests that an impaired
cardiac function at the stage of refractory ascites is important.
However, data on the consequences for survival with BB need
to be conﬁrmed [7]. Very high doses of BB, need to be used with
great care, or perhaps avoided in patients with refractory ascites.
Banding ligation can be substituted for BB, for the prevention of
variceal bleeding if BB are not being given.
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Letters to the EditorTo the Editor:
We read with great interest the paper by Sersté et al. regarding
effects of non-selective beta-blockers (BB) and paracentesis
induced circulatory dysfunction (PICD) [1]. This is the ﬁrst study
to explore the background for potential deleterious effects of BB
in refractory ascites, as suggested in a previous study by the
authors [2]. The high risk of PICD after BB treatment seems
related to an inability to increase heart rate during a circulatory
challenge. BB bind to b1 and b2-adrenoreceptors and thereby
compete with the binding of norepinephrine (NE) and epineph-
rine. Blocking the b1 receptors reduces the heart rate as well as
inotropy and hence the cardiac output even in decompensated
patients [3].
A low dose of selective BB in congestive heart failure has
been shown to have a cardioprotective effect possibly related
to a diminished beta-adrenergic drive on the diseased heart.
This may also be the case in cirrhosis. However, in cirrhosis
BB are generally titrated to maximum tolerable doses to reduce
risk of variceal bleeding. In this study, the mean dose was
132 mg/day and 7 out of 10 patients received 160 mg/day. This
level is higher, especially in the decompensated, than the doses
in most randomised trials with BB in the prevention of variceal
bleeding [2,4].
In the study by Sersté et al. 80% of the patients who
received BB developed PICD, which is more frequent than pre-
viously reported [5,6]. Whether this is related to the high BB
doses used is unclear [7], but nevertheless, intensive betablock-
ade and resultant decreased heart rate and cardiac output must
have been present. There is evidence that a chronotropic
incompetence partly based on down-regulation and desensiti-
sation of beta-receptors is involved in the cardiac dysfunction
in cirrhosis especially in the most advanced stages [8]. A fur-
ther pharmacological blockade of cardiac beta-receptors may
further compromise the cardiac function. The result is an aug-
mented cardiac counter-regulatory response to a sudden vaso-
dilatation-induced decrease in arterial blood pressure. In
decompensated cirrhosis, the circulation and perfusion of vital
organs are dependent on a sufﬁcient cardiac reserve. The nor-
mal circulatory response to a number of stressful events such
as for example PICD, infections, and haemorrhage is an increase
in cardiac output based on the ability to increase heart rate
and contractility to meet the increased demand of perfusion.
Thus, regulation of heart rate is the main physiological mecha-
nism to compensate for circulatory stress in patients partly
refractory to endogenous vasoconstrictors. The exact mecha-
nisms behind PICD is not fully understood, but two circulatory
challenges may be present namely the decreases in systemic
vascular resistance and central blood volume with decreased
venous return and therefore impaired cardiac ﬁlling and a
reduced cardiac output.
Thus, during PICD there is a further vasodilation, which is
partly resistant to the physiological counter-regulatory vasocon-
striction by the renin–angiotensin–aldosterone and sympatheticJournal of Hepatology 2012 vol. 56 j 298–302
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Pitavastatin enhances antiviral efﬁcacy of standard
pegylated interferon plus ribavirin in patients with chronic
hepatitis C: A prospective randomized pilot study
To the Editor:
We read the article by Harrison et al. [1] with great interest. The
authors performed a retrospective analysis of serum cholesterol
and statin use of patients in the IDEAL study. They found a signif-
icantly higher sustained virological response (SVR) among
patients who took a statin prior to antiviral therapy compared
to patients not using statins. However, this was not a prospective
trial and they did not show the combined effect of statins with
PEG-IFN plus ribavirin.
In vitro studies showed antiviral efﬁcacy with statins [2], but
pilot clinical trials showed no or modest beneﬁt [3–5]. Since insu-
lin resistance is increased in chronic hepatitis C infection [6,7]
and also insulin resistance impairs SVR rate to PEG-IFN plus riba-
virin [8]; improvement of insulin resistance with statin might
improve SVR. Pitavastatin is a statin approved in Japan in 2003
[9], and in the US in 2009 [10]. Of note, in vitro studies in the
HCV replicon system showed that pitavastatin reduced viral rep-
lication [11–13]. We performed a prospective, randomized, and
controlled pilot trial of standard PEG-IFN-2b plus ribavirin, with
or without the addition of pitavastatin, to prove if pitavastatin
therapy can enhance virus suppression and elimination.
A total of 42 CHC patients diagnosed with genotype 1b and
with a viral load >5.0 Log IU/ml, who were treated with PEG-
IFN-2b at 1.0–1.5 lg/kg/week, plus ribavirin at 800–1400 mg/
day or 48 weeks were randomly assigned to receiving pitavasta-
tin (1–2 mg/day) or no additional therapy for 48 weeks. Patients
with diabetes mellitus or fatty liver were excluded. No signiﬁcant
difference was observed in the cumulative dose of PEG-IFN and
RBV between the standard and pitavastatin treatment groups.
Viral load was monitored at 4, 8, 12, 24, and 48 weeks after
treatment initiation using TaqMan real-time PCR (BML, Inc.,
Japan, range of quantitation: 1.2–7.8 Log IU/ml). The level of
HCV-RNA, SVR rate, adverse events, serum AST, ALT, and creatine
kinase (CK) were evaluated and compared using the Mann–Whit-
ney U test.
The cumulative rate of patients in whom HCV-RNA became
undetectable by standard combination therapy or standard ther-
apy with added pitavastatin was 5% and 29% at 4 weeks
(p = 0.0408), 33% and 57% at 8 weeks (p = 0.1256), 48% and 81%
at 12 weeks (p = 0.0259), 62% and 86% at 24 weeks (p = 0.0830),
and 67% and 86% at 48 weeks (p = 0.1522), respectively
(Fig. 1A). SVR at 72 weeks was 67% for patients with triple ther-
apy compared to 48% for patients with standard therapy alone
(Fig. 1B). However, this difference did not yet reach statistical sig-
niﬁcance due to the low number of patients (p = 0.2123). No sig-
niﬁcant differences between those two groups were found in the
rate of adverse drug events. Furthermore, no signiﬁcant
differences were observed in serum AST, ALT, and CK levels
(not shown). There was no case in which the medication had to
be discontinued prematurely due to side effects.
In conclusion, in patients with CHC genotype 1b, the use of
pitavastatin with PEG-IFN plus ribavirin increased the rate of
patients with undetectable HCV viral load. Furthermore, the use
of pitavastatin with PEG-IFN plus ribavirin increased slightly
the SVR (not statistically signiﬁcant). Of note, the addition of pita-
vastatin caused no adverse effects, and treatment could be con-
tinued in all patients within this pilot trial. Therefore, the
addition of pitavastatin to standard antiviral therapy appears to
be a promising option to increase SVR in patients with CHC,
which will justify larger prospective clinical trials.
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Fig. 1. Cumulative rate of HCV patients whose HCV-RNA dropped to
undetectable levels and SVR rates of patients treated with standard PEG-IFN
plus ribavirin with or without pitavastatin. (A) The cumulative rate of patients
in whom HCV-RNA decreased to undetectable levels by PEG-IFN plus ribavirin or
by additional use of pitavastatin (1–2 mg/day) with PEG-IFN plus ribavirin was 5%
and 29% at 4 weeks (p = 0.0408) and 48% and 81% at 12 weeks (p = 0.0259),
respectively. (B) The SVR rate of the group without pitavastatin was 48% while
that of the group with pitavastatin was 67% at 72 weeks (p = 0.2123).
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